Table of Content

1. Introduction to TIGIT Inhibitor
1.1 Overview
1.2 Historical Perspective


2. Role of TIGIT Inhibitors in Cancer
2.1 Enhanced Anti-Tumor Effects
2.2 Reduced Immunosuppressive Functions
2.3 Augments Anti-Tumor Immunity


3. Role of TIGIT Inhibitors in HIV


4. Role of TIGIT in Autoimmune Disorders


5. Mechanism of TIGIT Inhibitor


6. Clinical Approaches to Target TIGIT
6.1 Therapeutic Monoclonal Antibodies
6.2 Bispecific Antibodies
6.3 Small Molecule Inhibitors


7. FDA Orphan Designation for Tiragolumab


8. Global TIGIT inhibitors Clinical Trials Overview
8.1 By Company
8.2 By Country
8.3 By Patient Segment


9. Global TIGIT inhibitors Clinical Trials Insight 2022
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III


10. Global TIGIT Inhibitor Market Dynamics
10.1 Market Drivers
10.2 Commercialization Challenges


11. Global TIGIT Inhibitor Market Future Outlook


12. Competitive Landscape
12.1 Acrus Biosciences
12.2 Agensus
12.3 Astellas Pharma
12.4 AstraZeneca
12.5 Beigene
12.6 Bristol Meyer Squibb
12.7 Compugen
12.8 Gilead Sciences
12.9 iTeos Therapeutics
12.10 Merck
12.11 Roche
12.12 Seagen
12.13 Seatle Genetics
12.14 Shanghai Helnius Biotech



List of Figures

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
Figure 3-1: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
Figure 4-1: TIGIT Associated Autoimmune Disorders
Figure 5-1: TIGIT Inhibitor – Proposed Mechanism of Action
Figure 5-2: TIGIT Inhibitor – Mechanism of Action
Figure 6-1: Binding Efficacy of Monoclonal Antibody
Figure 6-2: Binding Efficacy of Bispecific Antibodies
Figure 6-3: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 7-1: Tiragolumab - SKYSCRAPPER08 Phase-III Trial Initiation & Completion Year
Figure 8-1: Global – TIGIT Inhibitors Clinical Trials by Company, 2022
Figure 8-2: Global – TIGIT Inhibitors Clinical Trials by Country, 2022
Figure 8-3: Global – TIGIT Inhibitors Clinical Trials by Patient Segment, 2022
Figure 10-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-2: Global – TIGIT Inhibitor Market Drivers
Figure 10-3: Stages of Drug Development